MOLECULAR PARTNERS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.315 CHF | +2.47% |
|
-1.04% | -3.63% |
Presenter SpeechJames Quigley (Analysts)Right. So good morning and good afternoon, everyone. I...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
3.315
CHF
Average target price
9.35
CHF
Spread / Average Target
+182.05%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -3.63% | 118M | |
| +5.66% | 109B | |
| +11.23% | 105B | |
| -0.38% | 22.25B | |
| -12.15% | 22.09B | |
| -7.66% | 18.68B | |
| -36.52% | 17.58B | |
| -10.09% | 16.85B | |
| +3.33% | 13.76B | |
| +36.58% | 12.46B |
- Stock Market
- Equities
- MOLN Stock
- News Molecular Partners AG
- Transcript : Molecular Partners AG Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-10-2021 11